Efficacy and safety of tulosine in patients with prostatic adenoma


Cite item

Full Text

Abstract

The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA). Tulosine treatment relieved both obstructive and irritative symptoms, IPSS parameters improved by 8.0 ± 0.3 points, QoL - by 1.4 ± 0.1 points, Qmax - by 2.6 ± 0.3 ml/s. Ultrasound investigation found no significant changes in the adenoma size. Residual urine volume reduced from 42.4 to 19.7 ml (by 53.7%). Blood pressure lowered insignificantly. Side effects were mild. Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.

References

  1. Гориловский Л. М. Доброкачественная гиперплазия предстательной железы. В кн.: Гориловский Л. М. (ред.). Избранные главы гериатрической урологии. М.; 2000. 146-203.
  2. Винаров А. З., Асламазов Э. Г. Гиперплазия предстательной железы. Современное лечение. В кн.: 10-й Российский съезд урологов: Материалы. М.; 2002. 33-41.
  3. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostatic hyperplasia with age. J. Urol. (Baltimore) 1984; 132: 474-479.
  4. McVary K. T. BPH: epidemiology and comorbidities. Am. J. Manag. Care 2006; 12: S122-S128.
  5. Manzarbeitia F., Vela Navarrete R., Sarasa J. L. et al. BPH: Histological aspects of adenoma mononuclear cell infiltration. Eur. Urol. Suppl. 2006; 5 (2): 123.
  6. Speakman M. J. Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More than treating symptoms. Eur. Urol. Suppl. 2008; 7 (11): 680-689.
  7. Chapple Ch. R. The total approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) management: Introduction and conclusions. Eur. Urol. Suppl. 2003; 2 (7): 1-5.
  8. Teillac P. Facing the current challenges in benign prostatic hyperplasia. Eur. Urol. Suppl. 2007; 6 (6): 445.
  9. Schneider T. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Prevention or retention? Eur. Urol. Suppl. 2008; 7 (11): 696-701.
  10. Abrams P., Schulman C., Vaage S. Tamsulosin, a selective a1c-adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br. J. Urol. 1995; 76: 325-336.
  11. Schulman C. C., Cortvriend J., Jonas U. et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur. Urol. 1996; 29: 145-154.
  12. Abrams P. Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur. Urol. Suppl. 2005; 3: 8-16.
  13. Kirby R., Andersson K. E., Lerpor H., Steers W. D. Alpha(1)-adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostat. Dis. 2000; 3: 76-83.
  14. Kaplan S. A., Roehrborn C. G., McConnell J. D. et al. Baseline symptoms, uroflow, and post-void residual urine as predictor or bph clinical progression in the medically treated arms of the MTOPS trial. In: Program and abstracts of the American Urological Assocation 98-th Annual Meeting; April 26-May 1, 2003. Chicago; 2003. Abstr. 1289.
  15. Hurchison A., Farmer R., Chappte C. et al. The efficacy of treatment for LUTS/BPH, a study in 6 European countries. Eur. Urol. Suppl. 2005; 4 (3): 6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies